期刊文献+

CBZ-AAN-Dox新前药的计算机辅助设计及合成与活性检测

Studies on a novel doxorubicin prodrug with computer-aided design, synthesis and activity detection
下载PDF
导出
摘要 目的探究一种以多柔比星为母药的低毒新型抗肿瘤前药。方法采用Sybyl 8.0的Sketch模块进行前药的计算机辅助设计,通过多种短肽共价偶联多柔比星形成前药库。虚拟筛选后用化学方法合成前药,通过硅胶柱和凝胶柱进行纯化,HPLC法检测与鉴定,体外特异性酶解试验及细胞毒性试验进行活性检测。结果计算机辅助药物设计所得到的新型前药N-苄氧羰基-丙氨酰-丙氨酰-天冬酰胺-多柔比星物理及化学参数较好,其化学合成产物纯度为94%,其天冬酰胺内肽酶酶解Km和Vmax分别为(68±7)μmol/L,(3.9±0.6)μmol/(L·s),对2种体外培养肿瘤细胞株的毒性作用约降低了约90%。结论计算机辅助药物设计在指导多柔比星前药合成过程中具有参考意义;前药合成与分离纯化方法简单可靠,分离效果好;新合成前药细胞毒性降低,可被天冬酰胺内肽酶酶解。 Objective To explore a novel prodrug of short peptides covalently bound doxorubicin with reduced toxicity. Methods Sybyl 8.0 Sketch module was used for the targeting prodrug design, it was synthesized and purified by silica gel column. HPLC was used for the purification detection and identification. Specific enzyme activity detection tests and in vitro cytotoxicity were determined. Results A novel prodrug of N-benzyloxycarbonyl-alanyl- alanyl-Asn-doxorubicin with better physical and chemical parameters was obtained by the computer-aided drug design and then chemically synthesized. The purity was 94%. The prodrug asparagine endopeptidase digestion K and Vm~ were (68+7)gmol/L, (3.9+0.6)~unol/(L's) respectively. The toxicity of two kinds of tumor cell lines K562 and MCF- 7 in vitro were reduced by approximately 90%. Conclusion Computer-aided drug design is helpful to doxorubicin prodrug in guiding the synthesis process with a reference value. The prodrug synthesis and purification method is simple and reliable. The novel prodrug has lower cytotoxic and can be digested by asparagine endopeptidase enzyme.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2014年第7期503-506,共4页 Chinese Journal of Antibiotics
基金 广东省科技厅科技计划项目(No.201106) 广州市科技计划项目(2014J4100058) 中山市科技局项目(No.20101H021)
关键词 多柔比星 天冬酰胺内肽酶 前体药物 Doxorubicin Asparagin endopeptidase Prodrug
  • 相关文献

参考文献13

  • 1Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2009, 1 (4):415-425.
  • 2Batrakova E V, Li S, Brynskikh A M, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers[J]. J Control Rel, 2010, 143(3): 290-301.
  • 3Hanuovi V, Bouovi I, Sklov/t L. Possibilities to increase the effectiveness of doxorubicin in cancer cells killing[J]Drug Metab Rev, 2011, 43(4): 540-557.
  • 4Feridooni T, Hotchkiss A, Remley-Carr S, et al. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes[J]. PLoS One, 2011, 6(7): e22801.
  • 5Chen J M, Dando P M, Stevens R A, et al. Cloning and expression of mouse legumain, a lysosomal endopeptidase[J]. Biochem J, 1998, 335( Ptl): 111-117.
  • 6Dall E, Brandstetter H. Activation of legumain involves proteolytic and conformational events, resulting in a context- and substrate-dependent activity profile[J]. Acta Crystallogr SectFStructBiol Cryst Commun, 2012, 68(Pt 1): 24-31.
  • 7Briggs J J, Haugen M H, Johansen H T, et al. Cystatin E/ M suppresses legumain activity and invasion of human melanoma[J]. BMC Cancer, 2010, 10: 17.
  • 8Lewen S, Zhou H, Hu H D, et al. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis[J]. Cancer Immunol Immunother, 2008, 57(4): 507-515.
  • 9Mackay J A, Chen M, Mcdaniel J R, et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection[J]. Nat Mater, 2009, 8(12): 993-999.
  • 10Shahnaz G, Iqbal J, Rahmat D, et al. Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life[J]. J Control Release, 2012,157(3):375-382.

二级参考文献27

  • 1[2]Rosci.M,Horvat S.Transformations of bioactive peptides in the presence of sugars-Characterization and stability studies of the adducts generated via the Maillard reaction.Bioorg Med Chem,2006,14(14):4933-4943.
  • 2[3]Goodson RJ,Katre NV.Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site.Biotechnology,1990,8(4):343-346.
  • 3[5]Pan CQ,Buxton JM,Yung SL,et al.Design of a long acting peptide fFunctioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist.J Biol Chem,2006,281(18):12506-12515.
  • 4[6]Ligeti M,B.sze S,Csampai A,et al.Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue.J Pept Sci,2006,12(7):481-490.
  • 5[7]Zobel K,Koehler MF,Beresini MH,et al.Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo.Bioorg Med Chem Lett,2003,13(9):1513-1515.
  • 6[8]Chen Y,Vasil AI,Rehaume L,et al.Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.Chem Biol Drug Des,2006,67(2):162-173.
  • 7[9]Boeglin D,Xiang Z,Sorenson NB,et al.Aza-scanning of the potent melanocortin receptor agonist Ac-His-d-Phe-Arg-Trp-NH.Chem Biol Drug Des,2006,67(4):275-283.
  • 8[10]D'Ursi AM,Giannecchini S,Esposito C,et al.Development of antiviral fusion inhibitors:short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus.Chembiochem,2006,7(5):774-779.
  • 9[11]Zheng J,Ma B,Tsai CJ,et al.Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35.Biophys J,2006,91(3):824-833.
  • 10[12]Pless J.The history of somatostatin analogs.J Endocrinol Invest,2005,28(11 Suppl):1-4.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部